2024
Early vigabatrin to augment GABAergic pathways in post-anoxic status epilepticus
Maciel C, Ahmad B, Jose Bruzzone Giraldez M, Eisenschenk S, Ramsay E, Maranchick N, Peloquin C, Hirsch L, Busl K. Early vigabatrin to augment GABAergic pathways in post-anoxic status epilepticus. Epilepsy & Behavior 2024, 160: 110082. PMID: 39393141, DOI: 10.1016/j.yebeh.2024.110082.Peer-Reviewed Original ResearchStatus epilepticusGamma-aminobutyric acidGABAergic pathwayHypoxic-ischemic brain injuryPost-cardiac arrest periodHypoxic-ischemic insultOutcomes of patientsEffective adjunctive therapyInhibition of gamma-aminobutyric acidLondon-Innsbruck ColloquiumAdjunctive therapyAcute seizuresEffective therapyPoor outcomeEpilepticusExclusion criteriaEarly inhibitionSynergistic augmentationGamma-aminobutyric acid catabolismArrest periodTherapeutic nihilismSeizuresClinal trialsAllosteric modulatorsVigabatrin
2008
Cross-sensitivity of skin rashes with antiepileptic drug use
Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR, Bazil CW. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008, 71: 1527-1534. PMID: 18981374, DOI: 10.1212/01.wnl.0000334295.50403.4c.Peer-Reviewed Original ResearchConceptsRate of rashAntiepileptic drugsValproic acidSpecific antiepileptic drugsAntiepileptic drug useMore antiepileptic drugsCertain antiepileptic drugsAED selectionSkin rashIndividual patientsRashPatientsLamotrigineOxcarbazepineDrug usePhenytoinCarbamazepineLevetiracetamZonisamideGabapentinTiagabineVigabatrinClobazamDrugsMedications